Abstract
Background—: The objective of this study was to evaluate the added predictive ability of the CHA 2 DS 2 VASc prediction rule for stroke and death in a nonanticoagulated population of patients with atrial fibrillation. Methods and Results—: We included 1603 nonanticoagulated patients with incident atrial fibrillation from a Danish prospective cohort study of 57 053 middle-aged men and women. The Net Reclassification Improvement was calculated as a measure to estimate any overall improvement in reclassification with the CHA 2 DS 2 VASc sore as an alternative to the CHADS 2 score. After 1-year follow-up, crude incidence rates were 3.4 per 100 person-years for stroke and 13.6 for death. After a mean follow-up of 5.4 years (±3.7 years), the crude incidence rates for stroke and death were 1.9 and 5.6, respectively. During the entire observation period, the c-statistics and negative predictive values were similar for both risk scores. The Net Reclassification Improvement analysis showed that 1 of 10 reclassified atrial fibrillation patients would have been upgraded correctly using the CHA 2 DS 2 VASc score. Conclusions—: Both the CHADS 2 as well as the CHA 2 DS 2 VASc risk score can exclude a large proportion of patients from having high risk of stroke or death. However, using the CHA 2 DS 2 VASc risk score, fewer patients will fulfill the criterion for low risk (and are truly low risk for thromboembolism). For every 10 extra patients transferred to the treatment group at 5 years, using the CHA 2 DS 2 VASc risk score, 1 patient would have had a stroke that might have been avoided with effective treatment.

This publication has 21 references indexed in Scilit: